Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05469906
Starting soon Observational

Evaluation at 5 and 10 Years of Renal Transplant Patients

NCT05469906 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2022-07
Last updated
2022-07-22

Condition(s) studied

Transplant; Complication, Failure

Study summary

5 and 10 years follow-up of the oxyop study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * informed patients participating to the oxyop study * Patient having completed the OXYOP M12 follow-up visit * Patient agreeing to participate in the observational study Exclusion Criteria: * Opposition to the use his medical data * patient deceased or with graft lost before M48

Primary outcome measure(s)

  • eGFR — 10 years
    estimated GFR (CKDEPI)

Trial sites (1)

FacilityCityRegionStatus
CHRU Brest Brest France

More University Hospital, Brest trials in France

Management of Moderately Hypoxemic Thoracic Trauma Active, not recruiting
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii Active, not recruiting
Study on the Priorities of Patients Admitted to Intensive Care Starting soon
Descriptive Single-center Retrospective Study of a Series of Cases of Clavicle Pseudarthrosis: Epidemiology, Surgical Management, and Functional Outcomes Active, not recruiting
French Translation of The Female Sexual Distress Scale-Revised Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05469906 on ClinicalTrials.gov ↗ ← All trials in France